Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves’ Hyperthyroidism: The RISG Study
Table 2
Patient’s characteristics at time of randomization to either Arma A (observation) or Arm B (treatment with fixed low dose block-replace treatment, FLATD).
ARMA A (Observation)
ARMA B (FLATD)
P value (Arm A vs. Arm
Participant, n
33
33
-
Sex, M/F (%F)
3/30 (90.9)
9/24 (72.7)
0.108
Age, years, median IQR
43 (37 – 53)
46 (36 – 53)
0.649
History of hyperthyroidism, n (%)
2 (7.1)
1 (3.3)
0.605
Smoker, n (%)
9 (27.3)
7 (21.2)
0.775
Estrogen use, n (%)
5 (15.2)
6 (18.2)
0.559
GD in 1st generation relatives, n (%)
9 (27.3)
7 (21.2)
0.775
BMI kg/m2, median (IQR)
26.0 (22.9 – 28.9)
27.4 (24.3 – 32.0)
0.184
None or minor eye symptoms, n (%)
24 (72.7)
27 (81.8)
0.488
Time to remission in RISG1, months
13.7 (5.3)
13.6 (5.4)
0.945
Thyroid volume ml, median (IQR)
24 (16 – 32)
17 (12 – 24)
0.022
S-T4 nmol/L, median (IQR)
97 (83.5 – 111.5)
104 (87.5 – 112)
0.568
S-T3 nmol/L, median (IQR)
1.7 (1.4 – 1.8)
1.7 (1.4 – 2.0)
0.350
S-TRAb IU/L, median (IQR)
0.5 (0.3 – 0.75)
0.6 (0.3 – 0.8)
0.413
u-iodine, µg/L, median (IQR)
74.5 (45.5 – 133)
74 (41.5 – 103)
0.455
-Whitney or Chi square/Fisher exact test as appropriate. n = number. M = male. F = female. IQR = interquartile range.
